Rate of CVD Mortality, MI, Stroke Down for Patients on Semaglutide

This article originally appeared here.
Share this content:
Rate of CVD Mortality, MI, Stroke Down for Patients on Semaglutide
Rate of CVD Mortality, MI, Stroke Down for Patients on Semaglutide

FRIDAY, Sept. 16, 2016 (HealthDay News) -- Semaglutide is noninferior to placebo for patients with type 2 diabetes at high cardiovascular risk, according to a study published online Sept. 16 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 12 to 16 in Munich.

Steven P. Marso, M.D., from Research Medical Center in Kansas City, Mo., and colleagues randomized 3,297 patients with type 2 diabetes to receive once-weekly semaglutide or placebo for 104 weeks. At baseline, 83.0 percent of the patients had established cardiovascular disease, chronic kidney disease, or both.

The researchers found that the primary outcome (composite of first occurrence of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) occurred in 6.6 percent of patients in the semaglutide group and in 8.9 percent of the placebo group (hazard ratio, 0.74; 95 percent confidence interval, 0.58 to 0.95; P < 0.001 for noninferiority). Non-fatal myocardial infarction occurred in 2.9 and 3.9 percent of those receiving semaglutide and placebo, respectively (hazard ratio, 0.74; 95 percent confidence interval, 0.51 to 1.08), while nonfatal stroke occurred in 1.6 and 2.7 percent, respectively (hazard ratio, 0.61; 95 percent confidence interval, 0.38 to 0.99). The groups had similar rates of death from cardiovascular causes.

"The rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide," the authors write.

Several authors disclosed financial ties to Novo Nordisk, which manufactures semaglutide and funded the study.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »